ReviewBiomolecules2025
It Takes Two to Tango: Current Understanding of the Role of M16 Family of Proteases and Their Structural Properties.
Review in Biomolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The M16 protease family comprises metalloendopeptidases, characterized by a unique molecular architecture. The active enzyme molecule is composed of two halves, which together form a structure resembling a clam shell. Although the active site residues are typically located in only one half, both parts are essential for proper enzyme function. The M16 family includes many proteins that are crucial for the physiology of the organism and, therefore, are the subject of intensive research. The flagship examples are insulin-degrading enzyme (IDE), mitochondrial processing peptidases (MPPs), and mitochondrial and chloroplast presequence peptidases (PrePs). The substrates of these enzymes include many biologically important peptides, such as insulin and amyloid β. Therefore, M16 peptidases are considered attractive therapeutic targets, and understanding their structure and mechanism of action is essential for the development of specific and selective modulatory compounds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.